Integral Health Asset Management’s Sage Therapeutics SAGE Stock Holding History

Integral Health Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200,000	Closed	-$3.75M	–	99
2024 Q1	$3.75M	Hold	200,000	–	–	0.35%	71
2023 Q4	$4.33M	Buy	+200,000	New	+$3.96M	0.59%	57
2023 Q3	–	Sell	-80,000	Closed	-$3.76M	–	90
2023 Q2	$3.76M	Sell	80,000 -165,000	-67%	-$8.21M	0.47%	62
2023 Q1	$10.3M	Sell	245,000 -115,000	-32%	-$4.94M	2.07%	17
2022 Q4	$13.7M	Buy	360,000 +3,000	+0.8%	+$115K	2.88%	12
2022 Q3	$14M	Sell	357,000 -55,257	-13%	-$2.14M	2.72%	11
2022 Q2	$13.3M	Buy	412,257 +101,257	+33%	+$3.39M	2.74%	11
2022 Q1	$10.3M	Sell	311,000 -98,000	-24%	-$3.68M	2.68%	9
2021 Q4	$17.4M	Buy	409,000 +90,000	+28%	+$3.77M	4.81%	2
2021 Q3	$14.1M	Buy	319,000 +95,000	+42%	+$4.36M	4.06%	3
2021 Q2	$12.7M	Buy	224,000 +80,000	+56%	+$5.66M	3.5%	5
2021 Q1	$10.8M	Sell	144,000 -51,000	-26%	-$4.18M	3.08%	7
2020 Q4	$16.9M	Sell	195,000 -35,000	-15%	-$2.58M	5.02%	1
2020 Q3	$14.1M	Buy	230,000 +35,000	+18%	+$1.77M	4.3%	2
2020 Q2	$8.11M	Buy	195,000 +25,000	+15%	+$907K	2.43%	12
2020 Q1	$4.88M	Buy	170,000 +50,000	+42%	+$2.9M	2.15%	18
2019 Q4	$8.66M	Buy	+120,000	New	+$14.8M	3.37%	10

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Integral Health Asset Management's SAGE Position: Q2 2024 in Review

Integral Health Asset Management sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 200,000 shares — an estimated $3.75M sold.

Integral Health Asset Management first reported a position in SAGE in Q4 2019 and held it in 17 quarters. The position peaked at $17.4M in Q4 2021. 193 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

Integral Health Asset Management reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
Integral Health Asset Management sold 200,000 Sage Therapeutics shares in Q2 2024, an estimated $3.75M.
Integral Health Asset Management first reported a position in Sage Therapeutics in Q4 2019 and held it in 17 quarters.
Integral Health Asset Management's Sage Therapeutics position peaked at $17.4M in Q4 2021.
193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Integral Health Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.